Clinical Research Directory
Browse clinical research sites, groups, and studies.
Silica-Based Wound Treatment (Curi01) Plus Standard Care Versus Standard Care Alone for Chronic Diabetic Foot Wounds
Sponsor: Cutempa Medical AG
Summary
The goal of this clinical trial is to learn if Curi01, a powder made of silica (silicon dioxide) particles, helps chronic, oozing diabetic foot ulcers heal when it is added to standard wound care. Curi01 is sprinkled directly onto the wound, where it soaks up wound fluid and forms a gel that is washed off at the next dressing change. The main questions it aims to answer are: Do more wounds heal completely within 12 weeks when Curi01 is added to standard wound care, compared with standard wound care alone? A wound counts as healed when it is fully closed and still closed 14 days later. Is Curi01 safe and well tolerated? Researchers will compare Curi01 plus standard wound care to standard wound care alone. Standard wound care includes removing dead tissue, cleaning the wound, non-medicated dressings and pressure relief for the foot if applicable. Participants will: Be adults with type 1 or type 2 diabetes who have an oozing foot ulcer (2 to 10 cm²) that has been present for at least 6 weeks and has not improved enough with standard wound care First receive standard wound care for 2 weeks to check whether the wound improves on its own Then be assigned by chance to one of the two groups; 2 out of 3 participants will receive Curi01 Visit the study site up to 18 times over about 14 weeks; in the Curi01 group, the powder is applied at each visit until the wound is dry Have their wound photographed and measured with a wound imaging app at each visit Answer questionnaires about their quality of life and how they feel their condition has changed Be asked about any side effects or health problems About 280 participants will take part at around 20 study sites in Germany. Participants and doctors will know which treatment is being given.
Official title: A Randomized, Controlled Clinical Study to Investigate the Efficacy and Safety of a Physically Active SiO2-Aerosil Mixture (Curi01) in Addition to Standard of Care Versus Standard of Care Only in the Treatment of Chronic, Exudating Foot Wounds in Diabetic Patients (DFU)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
280
Start Date
2026-08-20
Completion Date
2028-02
Last Updated
2026-11-18
Healthy Volunteers
No
Conditions
Interventions
Curi01
Sterile, powder-based wound exudate adsorbing agent composed of two types of silicon dioxide particles. Applied topically to the target wound evenly and generously (layer of approx. 3-5 mm) until the wound surface is completely covered, then covered with a sterile dressing. Applied at each study visit for up to 12 weeks; may be stopped once the wound is dry and restarted if exudation resumes. Class IIb medical device, not CE-marked (investigational).
Standard of Care
Standard wound care as defined in the protocol: debridement (sharp/surgical or mechanical) as needed, wound cleansing with sterile saline or an approved antiseptic (polyhexanide, octenidine or chlorhexidine), non-active wound dressings without antimicrobial, pharmacologic or biological agents, offloading if applicable, and compression therapy if indicated.
Locations (13)
Diabetes Zentrum Bad Mergentheim
Bad Mergentheim, Germany
Studienzentrum Dr. Braun GmbH
Berlin, Germany
Klinikum Bremerhaven Reinkenheide gGmbH
Bremerhaven, Germany
Klinikum Chemnitz gGmbH
Chemnitz, Germany
DZDM - Diabetes Zentrum Duisburg Mitte
Duisburg, Germany
Universitätsklinikum Gießen und Marburg, Standort Gießen
Giessen, Germany
Hausarztzentrum Butendorf
Gladbeck, Germany
KRH Klinikum Siloah, Diabetologisches Fuß- und Wundzentrum
Hanover, Germany
Universitätsklinikum Jena
Jena, Germany
Diabetespraxis Kiel
Kiel, Germany
LMU Klinikum, Sektion Angiologie
München, Germany
Gemeinschaftspraxis Dres. Großkopf
Wallerfing, Germany
Helios Klinik Wuppertal, Zentrum für Dermatologie, Allergologie und Dermatochirurgie
Wuppertal, Germany